Breast cancer cells have a high capacity to acidify extracellular milieu by a dual mechanism.
The extracellular pH in malignant tumors is known to be lower than in normal tissues and may therefore facilitate extracellular activation of secreted lysosomal cathepsins. We have tested the capability of human mammary cells (continuous cell lines and primary culture) to acidify their extracellular environment, using two techniques. By measuring pH changes through alterations of phenolsulfone phthaleine absorbance, we found that the more aggressive MDA-MB-231 human breast cancer cells were more active in acidifying a non-buffered balanced salt solution than the estrogen receptor positive MCF7 and ZR75 cell lines and than normal mammary epithelial cells in primary culture. Metastatic breast cancer cells from pleural effusions were up to 200-fold more active in acidifying their extracellular milieu than non-malignant mammary cells cultured in the same conditions, strongly suggesting that this difference also occurs in vivo. The use of inhibitors in the presence or absence of glucose showed that both lactate and an ATP-driven proton pump sharing some characteristics of the vacuolar H+ pump were involved. Bafilomycin A1, a specific inhibitor of the vacuolar (V-type) ATP-H+ pump inhibited part of the acidification by MCF7 cells, but not by MDA-MB-231 cells. We also used microelectrodes to measure extracellular pH, in close contact to the MCF7 breast cancer cells. The pH at the free surface of MCF7 cells was lower by 0.33 +/- 0.14 unit than that of the surrounding medium, while insertion of the microelectrode tip beneath the attached surface of the cells showed a greater lowering of pH from 0.3 to 1.7 pH unit as long as cell attachment on the substrate prevented H+ diffusion. We conclude that breast carcinoma cells have a higher capacity for acidifying their extracellular milieu than normal mammary cells, and that both a plasma membrane H(+)-ATPase, and lactic acid production are involved in this acidification. It is therefore possible that the aspartyl and cysteinyl pro-cathepsins secreted in excess by tumor cells may be activated extracellularly in vivo close to the basement membrane.
Montcourrier
P
P
Unité Hormones et Cancer (U 148) INSERM, Montpellier, France.
Silver
I
I
Farnoud
R
R
Bird
I
I
Rochefort
H
H
D000143:Acids; D000584:Amiloride / Q000494:pharmacology; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D001940:Breast / Q000166:cytology; D001943:Breast Neoplasms / Q000737:chemistry* / Q000378:metabolism / Q000473:pathology; D002478:Cells, Cultured; D005110:Extracellular Space / Q000737:chemistry*; D005947:Glucose / Q000378:metabolism; D006801:Humans; D006863:Hydrogen-Ion Concentration; D019344:Lactic Acid / Q000378:metabolism; D018942:Macrolides; D008264:Macrophages / Q000737:chemistry / Q000166:cytology / Q000378:metabolism; D008839:Microelectrodes; D009840:Oligomycins / Q000494:pharmacology; D054328:Proton Pump Inhibitors; D006180:Proton-Translocating ATPases / Q000378:metabolism; D014407:Tumor Cells, Cultured
D000143:Acids; D000900:Anti-Bacterial Agents; D018942:Macrolides; D009840:Oligomycins; D054328:Proton Pump Inhibitors; D019344:Lactic Acid; D000584:Amiloride; C040929:bafilomycin A1; D006180:Proton-Translocating ATPases; D005947:Glucose